Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Xiaoque Xie
miR‑138‑5p Modulates the Expression of Excision Repair Cross‑complementing Proteins ERCC1 and ERCC4, and Regulates the Sensitivity of Gastric Cancer Cells to Cisplatin
Oncology Reports
Medicine
Cancer Research
Oncology
Progress in the Study on PD-L1 Inhibitor in the Treatment of EGFR-Mutant Non-Small Cell Lung Cancer
Clinical Oncology and Research
Related publications
ERCC1 (Excision Repair Complementing Defective Repair in Chinese Hamster)
Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer Research
Oncology
Genetics
Hematology
miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics
Molecular Cancer Research
Cancer Research
Oncology
Molecular Biology
AB153. Down-Regulated Expression of Excision of Repair Cross-Complementing Gene 1 Reduces Resistance to Hydroxycamptothecine in Bladder Cancer
Translational Andrology and Urology
Reproductive Medicine
Urology
Excision Repair Cross-Complementing Group-1 (ERCC1) Induction Kinetics and Polymorphism Are Markers of Inferior Outcome in Patients With Colorectal Cancer Treated With Oxaliplatin
Oncotarget
Oncology
The Clinical Significance of Downregulation of Mir-124-3p, Mir-146a-5p, Mir-155-5p and Mir-335-5p in Gastric Cancer Tumorigenesis
International Journal of Oncology
Cancer Research
Oncology
MIR-138-5P Inhibits the Progression of Prostate Cancer by Targeting FOXC1
Molecular genetics & genomic medicine
Genetics
Molecular Biology
Excision Repair Cross-Complementing Group 1 May Predict the Efficacy of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer
Clinical Cancer Research
Cancer Research
Oncology
Prognostic Value of Excision Repair Cross-Complementation Group 1 Expression in Gastric Cancer: A Meta-Analysis
Experimental and Therapeutic Medicine
Medicine
Cancer Research
Immunology
Microbiology
The Tumor Suppressor miR-138-5p Targets PD-L1 in Colorectal Cancer
Oncotarget
Oncology
